Published in Cancer Res on February 01, 1998
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest (2001) 3.01
Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev (2003) 2.76
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer (2003) 2.43
Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J (2008) 1.78
Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer (2002) 1.49
P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J (2002) 1.48
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol (2002) 1.46
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer (2005) 1.39
Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer (2006) 1.32
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab (2001) 1.31
Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer (2000) 1.31
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol (2000) 1.27
Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer (1999) 1.25
Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog (2007) 1.24
Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer (1999) 1.22
Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) (2011) 1.20
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol (2002) 1.19
Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18
Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol (2005) 1.13
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol (2006) 1.13
Drug repurposing: far beyond new targets for old drugs. AAPS J (2012) 1.09
The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest Ophthalmol Vis Sci (2009) 1.07
Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann Surg (2005) 1.07
Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07
Apigenin prevents UVB-induced cyclooxygenase 2 expression: coupled mRNA stabilization and translational inhibition. Mol Cell Biol (2006) 1.05
Immune mechanisms in thyroid eye disease. Thyroid (2008) 1.05
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int J Mol Sci (2011) 1.04
Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res (Phila) (2011) 1.04
Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res (2009) 1.03
A review of the anticancer potential of the antimalarial herbal cryptolepis sanguinolenta and its major alkaloid cryptolepine. Ghana Med J (2013) 1.01
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia (2001) 1.00
Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol (2003) 1.00
Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells. Exp Eye Res (2010) 0.99
Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut (2001) 0.99
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia (2001) 0.99
Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia (2001) 0.98
Chemoprevention of gastric cancer by celecoxib in rats. Gut (2004) 0.98
Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci U S A (2003) 0.97
Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription. J Biol Chem (2008) 0.97
Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev Res (Phila) (2009) 0.97
NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res (2013) 0.96
Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci (2001) 0.96
Chemopreventive potential of natural compounds in head and neck cancer. Nutr Cancer (2010) 0.95
Nicotine enhances migration and invasion of human esophageal squamous carcinoma cells which is inhibited by nimesulide. World J Gastroenterol (2009) 0.94
Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis. Br J Cancer (2003) 0.94
Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia (1999) 0.94
Aspirin and other anti-inflammatory drugs. Thorax (2000) 0.93
Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol (2003) 0.93
Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol (2004) 0.93
Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res (2000) 0.91
Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients. Virchows Arch (2009) 0.91
Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia (2003) 0.91
Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res (Phila) (2011) 0.90
The flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective molecules. PLoS One (2007) 0.89
Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer. Gastroenterol Res Pract (2011) 0.89
Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol (2003) 0.89
Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. World J Gastroenterol (2008) 0.88
The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull (2009) 0.88
Effect of cyclooxygenase genotype and dietary fish oil on colonic eicosanoids in mice. J Nutr Biochem (2011) 0.87
Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells. Exp Cell Res (2006) 0.87
Rosmarinic acid antagonizes activator protein-1-dependent activation of cyclooxygenase-2 expression in human cancer and nonmalignant cell lines. J Nutr (2008) 0.86
Effect of sphingosine kinase 1 inhibition on blood pressure. FASEB J (2012) 0.86
Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas. Cancer Prev Res (Phila) (2011) 0.86
Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. World J Gastroenterol (2014) 0.86
Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention. J Invest Dermatol (2014) 0.86
Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer. Bioorg Med Chem Lett (2009) 0.86
Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer (2006) 0.86
Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. PPAR Res (2008) 0.85
Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines. J Gastroenterol (2008) 0.85
Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Pathol (2002) 0.85
COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. Int J Med Sci (2012) 0.85
Chemopreventive effect of celecoxib in oral precancers and cancers. Laryngoscope (2006) 0.84
COX-2 expression and tumor angiogenesis in colorectal cancer. World J Gastroenterol (2004) 0.84
Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors? Br J Cancer (2003) 0.83
Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells. Int J Mol Sci (2014) 0.83
Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. Childs Nerv Syst (2010) 0.82
Cyclooxygenase-2 expression and its association with thyroid lesions. Arch Med Sci (2010) 0.82
Kimchi protects against azoxymethane/dextran sulfate sodium-induced colorectal carcinogenesis in mice. J Med Food (2014) 0.81
Baicalein inhibits DMBA/TPA-induced skin tumorigenesis in mice by modulating proliferation, apoptosis, and inflammation. Inflammation (2013) 0.81
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. Clin Exp Metastasis (2004) 0.81
Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br J Ophthalmol (2005) 0.81
Celecoxib enhances the detoxification of diethylnitrosamine in rat liver cancer. World J Gastroenterol (2009) 0.80
Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer. Med Chem Res (2014) 0.80
Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis. Neoplasia (2013) 0.80
Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines. Dig Dis Sci (2007) 0.80
Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: From experimental models to clinical trials. World J Biol Chem (2016) 0.79
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology (2015) 0.79
Elevated cyclooxygenase-2 expression in patients with early gastric cancer in the gastric pylorus. J Gastroenterol (2005) 0.79
Cyclooxygenase-2 inhibitors: promise or peril? Mediators Inflamm (2002) 0.79
Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am J Obstet Gynecol (2008) 0.79
Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgrad Med J (2005) 0.79
In vivo optical molecular imaging of matrix metalloproteinase activity following celecoxib therapy for colorectal cancer. Mol Imaging (2012) 0.79
The current status of chemoprevention in FAP. Fam Cancer (2006) 0.78
Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas. World J Gastroenterol (2004) 0.78
Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs. Br J Cancer (2004) 0.78
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1997) 5.11
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res (2000) 4.18
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A (1994) 4.15
Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A (1993) 3.93
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem (1990) 3.34
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A (1998) 2.71
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest (1990) 2.66
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A (1992) 2.55
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med (1996) 2.28
Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res (1977) 2.15
Randomized clinical trial of multimodal optimization of surgical care in patients undergoing major colonic resection. Br J Surg (2005) 2.13
Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res (1999) 2.13
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res (2000) 2.12
Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis (2000) 2.06
Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer (1977) 2.03
Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science (1998) 2.03
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res (2000) 1.96
Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res (1995) 1.96
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog (1999) 1.95
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res (2000) 1.88
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res (2000) 1.84
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem (2000) 1.84
Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology (1996) 1.81
Microflora and deconjugation of bile acids in alkaline reflux after partial gastrectomy. Am J Surg (1980) 1.78
Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J (1995) 1.74
Large-bowel carcinogenesis: fecal constituents of populations with diverse incidence rates of colon cancer. J Natl Cancer Inst (1973) 1.70
Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J (1999) 1.64
Multiple pituitary and ovarian defects in Krox-24 (NGFI-A, Egr-1)-targeted mice. Mol Endocrinol (1998) 1.62
A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem (1996) 1.61
The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis (1998) 1.59
Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest (1994) 1.59
Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res (1996) 1.58
Sequence analysis of VP4 and VP7 genes of nontypeable strains identifies a new pair of outer capsid proteins representing novel P and G genotypes in bovine rotaviruses. Virology (2000) 1.55
Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest (1997) 1.54
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (1993) 1.54
Promoting effect of sodium deoxycholate on colon adenocarcinomas in germfree rats. J Natl Cancer Inst (1976) 1.52
Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene. Mol Endocrinol (2001) 1.52
Lepromatous leprosy with extensive truncal seborrheic keratoses and acral verruca vulgaris. Int J Dermatol (1994) 1.49
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res (1995) 1.48
Review article: bacterial translocation in the critically ill--evidence and methods of prevention. Aliment Pharmacol Ther (2007) 1.45
Diet and excretion of bile acids. Cancer Res (1981) 1.44
Implantable cardioverter defibrillator utilization among device recipients presenting exclusively with syncope or near-syncope. J Cardiovasc Electrophysiol (1997) 1.42
Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res (2001) 1.41
Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res (1997) 1.41
Balloon mitral valvuloplasty with bifoil catheter: immediate and long-term follow-up results. Cathet Cardiovasc Diagn (1998) 1.38
The 1982 epidemic of dengue fever in Delhi. Indian J Med Res (1985) 1.38
Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol (1995) 1.37
Tumor promotion by dietary fat in azoxymethane-induced colon carcinogenesis in female F344 rats: influence of amount and source of dietary fat. J Natl Cancer Inst (1984) 1.37
Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab (2002) 1.37
Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Res (1975) 1.35
Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest (1995) 1.33
Nutrition and its relationship to cancer. Adv Cancer Res (1980) 1.29
16S ribosomal DNA terminal restriction fragment pattern analysis of bacterial communities in feces of rats fed Lactobacillus acidophilus NCFM. Appl Environ Microbiol (2001) 1.28
Dengue fever in India. Indian J Pediatr (1987) 1.27
Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology (1993) 1.27
COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci (1999) 1.25
Fecal profiles of anaerobic microflora of large bowel cancer patients and patients with nonhereditary large bowel polyps. Cancer Res (1978) 1.24
Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res (1993) 1.22
Investigation on the outbreak of influenza by A/USSR/77 virus strain in Pune, Maharashtra in 1978. Indian J Med Res (1979) 1.21
Conformational flexibility in DNA structure as revealed by structural studies of drug intercalation and its broader implications in understanding the organization of DNA in chromatin. Cold Spring Harb Symp Quant Biol (1978) 1.20
Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int (2006) 1.20
Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis (1993) 1.20
Novel expression of human chorionic gonadotropin/luteinizing hormone receptor gene in brain. Endocrinology (1993) 1.19
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther (1997) 1.18
The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab (1990) 1.18
Novel role of human chorionic gonadotropin in differentiation of human cytotrophoblasts. Endocrinology (1993) 1.17
Intestinal disaccharidase activities in the growing germfree and conventional rats. Arch Biochem Biophys (1966) 1.17
Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology (1999) 1.16
Chemoprevention of colon carcinogenesis by organosulfur compounds. Cancer Res (1993) 1.15
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J (2001) 1.14
Iron and copper utilization in rabbits as affected by diet and germfree status. J Nutr (1965) 1.14
Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res (1997) 1.13
Metabolic epidemiology of colorectal cancer. Cancer (1974) 1.12
In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther (1994) 1.12
Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology (1995) 1.12
Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer (1980) 1.12
Metabolic epidemiology of large bowel cancer: fecal bulk and constituents of high-risk North American and low-risk Finnish population. Cancer (1978) 1.12
Bacterial translocation studied in 927 patients over 13 years. Br J Surg (2006) 1.11
Effects of high risk and low risk diets for colon carcinogenesis on fecal microflora and steroids in man. J Nutr (1975) 1.11
Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis (1999) 1.10
Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res (1999) 1.10
Pancreatic enzymes in germfree and conventional rats fed chemically defined, water-soluble diet free from natural substrates. J Nutr (1969) 1.10
Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis (1997) 1.09
Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am (1996) 1.08
Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res (1997) 1.08
Effects of dietary fat level and dimethylhydrazine on fecal acid and neutral sterol excretion and colon carcinogenesis in rats. J Natl Cancer Inst (1974) 1.08
Effect of dietary fish oil on azoxymethane-induced colon carcinogenesis in male F344 rats. Cancer Res (1986) 1.07
Enhancement of experimental colon cancer by genistein. Cancer Res (1997) 1.07
Dietary fat and its relationship to large bowel cancer. Cancer Res (1981) 1.06
Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol (1992) 1.05
Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog (1998) 1.05